TG4070

TG4070 – Phase 1 trial: Evaluation in Combination with Nivolumab in Resected Non-Small Cell Lung Cancer (NSCLC) Patients   TG4070 TG4070 is the second Individualized Neoantigen Therapeutic Vaccine (INTV) candidate derived from our proprietary myvac® platform, expanding into non-small cell lung cancer (NSCLC). TG4070 is being evaluated in a Phase 1 trial in combination with… Continue reading TG4070

TG6050

  TG6050 TG6050 an innovative oncolytic virus from the Invir.IO® platform. TG6050 has been engineered to express into the tumor, human IL-12, a cytokine that triggers a powerful antitumor immune response, and a full length anti-CTLA4 antibody.   Specifically multiply and induce tumor cell lysis (or oncolysis).   Discover how TG6050 works * requires analytics… Continue reading TG6050

teaser produits : tg6050

TG6050 is an innovative oncolytic virus from the Invir.IO® platform. It has been engineered to express human IL-12, a cytokine that triggers a powerful antitumor immune response, and a full length anti-CTLA4 antibody. More information on clinicaltrial.gov Read more on TG6050 Oncolytic virus mode of action

teaser produits : Research & Innovation

  “Transgene has a highly promising preclinical research pipeline. Our goal is to harness the power of viral vectors to unlock next generation immunotherapies that can transform the way we treat disease.”   Read our scientific presentations & publications

teaser tg-mva

TG-MVA Development of an MVA-based prophylactic vaccine candidate against mpox. Download the fact sheet Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line-Derived MVA Vaccine Cadidate (TG-MVA) at WCID 2026. Download the press release N. Silvestre, et al. World Congress on Infectious Diseases WCID 2026 – Abstract available… Continue reading teaser tg-mva

teaser produits : placeholder

WHO Third declaration within six months of Mpox as a Public Health Emergency of International Concern (PHEIC) (February 2025) 1 1 Third meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox 2024 Read more goes to a dedicated “Placeholder2” page  

teaser produits: TG4070

TG4070 is the second Individualized Neoantigen Therapeutic Vaccine from our proprietary myvac® discovery platform. The randomized Phase 1 will evaluate TG4070 in combination with nivolumab in resected non-small cell lung cancer (NSCLC) patients. More information on the Clinical Trial in the European Union – EMA EUCT2025-520946-31-00 Read more about TG4070 Discover TG4070

annonce kol event

LIVE Q&A KOL EVENTTG4050: Individualized cancer Vaccinein HPV-Negative Head & Neck Cancers April 19, 2023 | 12:00 PM ET CLICK TO REGISTER & ATTEND

annonceR&D

Find Out How Transgene’s Virus Powered ImmunotherapiesCan Transform the Treatment of Solid Tumors R&D Day – ParisSeptember 27, 2022 Detailed Program – Watch the webcast – Presentation

TG4050

Phase 1 part: Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with TG4050 in Head and Neck Cancer   TG4050 The lead Individualized Neoantigen Therapeutic Vaccine (INTV) from our myvac® platform, TG4050 is being further evaluated in a randomized multicenter Phase 2 part of a Phase 1/2 trial as a single agent… Continue reading TG4050